

THE SELECTION AND USE OF ESSENTIAL MEDICINES

Report of the WHO Expert Committee, 2009
(including the 16th WHO Model List of Essential Medicines
and the 2nd WHO Model List of Essential Medicines for Children)



**World Health
Organization**

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF 168.00/US\$ 151.00 (CHF 128.40/US\$ 115.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

958

THE SELECTION AND USE OF ESSENTIAL MEDICINES

Report of the WHO Expert Committee, 2009
(including the 16th WHO Model List of Essential Medicines and
the 2nd WHO Model List of Essential Medicines for Children)



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The selection and use of essential medicines: report of the WHO Expert Committee, March 2009 (including the 16th WHO model list of essential medicines and the 2nd WHO model list of essential medicines for children).

(WHO technical report series; 958)

1. Essential drugs - administration and dosage. 2. Drug information services. 3. Drug utilization. 4. Child. I. World Health Organization. II. Series.

ISBN 978 92 4 120958 8

(NLM Classification: QV 55)

ISSN 0512-3054

© World Health Organization 2009

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Switzerland
Printed in Switzerland**

Contents

PART ONE: 17th Expert Committee on the Selection and Use of Essential Medicines

vii

Declaration of interests of Members of the 17th Expert Committee on the Selection and Use of Essential Medicines

xi

1. Introduction	1
2. Open session	1
3. Proposal for revision of listing of pharmaceutical products	5
4. Review of other matters	6
5. Review of missing essential medicines for HIV	8
6. Review of the report of the Second Subcommittee and of the provisional Second List of Essential Medicines for Children	9
7. New applications for paediatric medicines	13
Section 6. Anti-infective medicines	13
Section 6.2. Antibacterials	13
Procaine benzylpenicillin (review) – (EMLc)	13
Section 6.2.4. Antituberculosis medicines (review, EMLc)	15
Section 6.3. Antifungal medicines	16
Liposomal amphotericin B (inclusion in the EMLc)	16
Section 6.5. Antiprotozoal medicines	17
Section 6.5.3. Antimalarial medicines	17
Artemether + lumefantrine (inclusion in the EMLc)	17
Section 7. Antimigraine medicines	18
Ibuprofen (inclusion in the EMLc)	18
Section 12. Cardiovascular medicines	18
Section 12.4. Medicines used in heart failure	18
Captopril (inclusion in the EMLc)	18
Carvedilol (Inclusion in the EMLc)	19
Section 17. Gastrointestinal medicines	19
Section 17.2. Antiemetic medicines (Inclusion of ondansetron in the EMLc)	19
Section 18. Hormones	20
Section 18.5. Insulins and other antidiabetic agents	20
Access to essential diabetes medicines for children in the developing world	20
8. Review of the comments on the Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children	20
9. Applications for the 16th WHO Model List of Essential Medicines	22
Section 4. Antidotes and other substances used in poisonings	22
Section 4.2. Specific	22
Pralidoxime (inclusion)	22
Section 5. Anticonvulsants/antiepileptics	23
Lamotrigine (inclusion)	23

	Addition of lorazepam and midazolam	24
	Lorazepam (inclusion)	24
	Midazolam (inclusion)	24
Section 6.	Anti-infective medicines	25
Section 6.2.	Antibacterials	25
Section 6.2.4.	Antituberculosis medicines	25
Rifabutin (inclusion)		25
Section 6.4.	Antiviral medicines	26
Section 6.4.2.	Antiretrovirals	26
Atazanavir (inclusion)		26
Protease inhibitors (review)		27
Fixed-dose combinations		29
Zidovudine + lamivudine + abacavir (AZT/3TC/ABC) (inclusion)		29
Section 6.4.3.	Other antivirals	31
Amantadine and rimantadine, oseltamivir, zanamivir (inclusion)		31
Section 6.5.	Antiprotozoal medicines	32
Section 6.5.5.	Antitrypanosomal medicines	32
Nifurtimox + efloornithine (inclusion)		32
Section 7.	Antimigraine medicines	33
	Sumatriptan (inclusion)	33
Section 8.	Antineoplastic, immunosuppressives and medicines used in palliative care	34
Section 8.2.	Cytotoxic medicines	34
Carboplatin (inclusion)		34
Hydroxycarbamide (inclusion)		35
Ifosfamide (inclusion)		36
Mesna (inclusion)		37
Section 10.	Medicines affecting the blood	38
	Tranexamic acid (inclusion)	38
Section 12.	Cardiovascular medicines	38
Section 12.2.	Antiarrhythmic medicines	38
Amiodarone (inclusion)		38
Section 12.4.	Medicines used in heart failure	39
Hydrochlorothiazide (new formulations)		39
Quinidine (deletion)		40
Section 17.	Gastrointestinal medicines	41
Section 17.1.	Antacids and other antiulcer medicines	41
Omeprazole (inclusion)		41
Section 17.5.	Medicines used in diarrhoea	42
Endar (inclusion)		42
Oral rehydration salts (inclusion)		42
Section 22.	Oxytocics and antioxytocics	43
	Misoprostol (inclusion)	43
Section 24.	Psychotherapeutic medicines	44
Section 24.1.	Medicines used in psychotic disorders	44
Clozapine, olanzapine, risperidone, quetiapine, aripiprazole and ziprasidone (inclusion)		44

Section 24.2. Medicines used in mood disorders	45
Section 24.2.1. Medicines used in depressive disorders	45
Fluoxetine, paroxetine and sertraline (inclusion)	45
Section 24.3. Medicines used in generalized anxiety and sleep disorders	46
Addition of a selective-serotonin reuptake inhibitor (escitalopram, paroxetine and sertraline)	46
Section 24.5. Medicines used in substance dependence programmes	47
Nicotine replacement therapy (inclusion)	47
Section 25. Medicines acting on the respiratory tract	48
Section 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease	48
Beclometasone (new formulation)	48
Cromoglicic acid (reinstatement)	48
10. Summary of recommendations	49
Additions, changes and deletions to the Model List	49
Additions, changes and deletions to the EMLc	53
Appendix 1	
Proposed lists of priority essential medicines for HIV	54
Appendix 2	
Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children	58
Annex 1	
The 16th WHO Model List of Essential Medicines	70
Annex 2	
The 2nd WHO Model List of Essential Medicines for Children	106
Annex 3	
The Anatomical Therapeutic Chemical (ATC) classification system	138
Annex 4	
Alphabetical list of essential medicines (with ATC classification code numbers)	159
PART TWO: Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines	169
1. Introduction	173
2. Open session	173
3. Review of terms of reference	174
4. The WHO Model List of Essential Medicines for Children – by section	183
Section 4. Antidotes and other substances used in poisonings	183
Section 4.1. Non-specific	183
Charcoal, activated (review)	183
Section 4.2. Specific	184
Acetylcysteine (review)	184
Pralidoxime (inclusion)	185

Section 6.	Anti-infective medicines	186
Section 6.2.	Antibacterials	186
Section 6.2.1.	Beta-lactam medicines	186
	Cefalexin (inclusion)	186
	Procaine benzylpenicillin (review)	187
	Ceftazidime (review)	188
	Ceftriaxone	189
	Carbapenems (review)	190
Section 6.2.2.	Other antibacterials	191
	Fluoroquinolones (review)	193
	Tetracycline (review)	195
	Gentamicin (review)	196
	Sulfadiazine (review)	197
Section 6.2.4.	Antituberculosis medicines (review)	198
Section 6.4.2.	Antiretrovirals (new formulations)	199
Section 6.5.	Antiprotozoal medicines	201
Section 6.5.2.	Antileishmaniasis medicines	201
	Liposomal amphotericin B (inclusion)	201
Section 8.	Antineoplastic, immunosuppressives and medicines used in palliative care	202
Section 8.2.	Cytotoxic medicines (review)	202
Section 8.4.	Medicines used in palliative care (inclusion)	204
Section 12.	Cardiovascular medicines	206
	Quinidine (review)	206
	Rheumatic fever and rheumatic heart disease (review)	206
Section 13.	Dermatological medicines (topical)	207
	Dermatological medicines (review)	207
Section 15.	Disinfectants and antiseptics	209
	Chlorhexidine (new formulation)	209
Section 17.	Gastrointestinal medicines	210
	Pancreatic enzymes (inclusion)	210
Section 17.2.	Antiemetic medicines (review)	211
Section 18.	Hormones, other endocrine medicines and contraceptives	211
	Hydrocortisone and fludrocortisone (inclusion)	211
Section 24.	Psychotherapeutic medicines (review)	212
Section 25.	Medicines acting on the respiratory tract	213
	Salbutamol (review)	213
Section 27.	Vitamins and minerals	214
	Biotin	214

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29309

